Solstice Advanced Materials beats Q3 revenue estimates on segment growth, raises FY outlook

By Reuters News


Overview

  • US specialty materials firm's Q3 revenue rose 8% yr/yr, beating analyst expectations

  • Adjusted EBITDA for Q3 grew 13% and beat analyst expectations

  • Company repurchased $100 mln in shares, aims to complete $500 mln buyback by Q1 2027


Outlook

  • Solstice raises 2026 net sales guidance to $4.195-$4.22 bln from $4.125-$4.185 bln

  • Company now expects 2026 adjusted EBITDA of $1.05-$1.06 bln, up from $1.035-$1.055 bln

  • Solstice forecasts 2026 adjusted diluted EPS of $2.90-$2.95, up from $2.75-$2.95


Result Drivers

  • SEGMENT GROWTH - Electronic Materials net sales rose 31% on higher demand for sputtering targets and thermal solutions in memory and AI applications

  • HEALTHCARE PACKAGING RECOVERY - Healthcare Packaging net sales increased 24% following destocking in the second half of 2025, supported by higher volume and pricing

  • REFRIGERANTS DEMAND - Refrigerants net sales grew 8% on strong demand across automotive and data center applications


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.05 bln

$1.02 bln (7 Analysts)

Q3 Adjusted EPS

$0.80

Q3 EPS

$0.50

Q3 Adjusted EBITDA

Beat

$265 mln

$254.35 mln (7 Analysts)

Q3 Adjusted EBITDA Margin

25.30%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the specialty chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Solstice Advanced Materials Inc is $80.50, about 30.4% above its November 3 closing price of $61.74


Reuters Recommended Reads

  • Nov 3 - Ashland Q4 adjusted profit misses estimates; forecasts higher 2027 sales

  • Nov 3 - Specialty chemicals supplier Innospec's Q3 revenue slightly misses estimates

  • Nov 3 - DuPont raises annual profit forecasts, sees upbeat Q4 on healthcare, aerospace strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.